Your browser doesn't support javascript.
loading
Prognosis of heart transplant patients in Mashhad University of Medical Sciences.
Teshnisi, Mohammad Abbasi; Vakilian, Farveh; Zirak, Nahid; Sedaghat, Alireza; Hoseini Khah, Seyed Hamid Reza; Mohammadpoor, Amir Hooshang; Azmonfar, Vahab; Keshtan, Farideh Golhasani; Rohani, Masoumeh; Bagheri, Reza; Ardehali, Abbas.
Afiliação
  • Teshnisi MA; Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Vakilian F; Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Zirak N; Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Sedaghat A; Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Hoseini Khah SHR; Mashhad University of Medical Sciences, Mashhad, Iran.
  • Mohammadpoor AH; Mashhad University of Medical Sciences, Mashhad, Iran.
  • Azmonfar V; Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Keshtan FG; Mashhad University of Medical Sciences, Mashhad, Iran.
  • Rohani M; Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Bagheri R; Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Ardehali A; Thoracic Surgeon Ronald Reagan UCLA Medical Center, Santa Monica, USA.
Kardiochir Torakochirurgia Pol ; 17(1): 33-38, 2020 Mar.
Article em En | MEDLINE | ID: mdl-32728361
ABSTRACT

INTRODUCTION:

Heart transplant is the ultimate treatment for patients with end-stage heart failure.

AIM:

To assess 50 heart transplant patients for underlying diseases, transplantation outcome and mortality rate during a 5-year follow-up program. MATERIAL AND

METHODS:

Fifty heart transplant patients who underwent heart transplantation from 2012 to 2017 were assessed for underlying diseases, organ rejection, duration of hospitalization, extubation time, cardiac output and survival. Biopsy samples were obtained after surgery for evaluation of rejection.

RESULTS:

Dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) were the most common underlying diseases with prevalence of 56% and 12%, respectively. Significant improvement in ejection fraction was observed following heart transplant. Minimum and maximum extubation and hospitalization times were 3-408 hours and 1-51 days, respectively. Organ rejection evaluation 10 days after heart transplantation revealed that 50% of patients did not show any rejection while 10% had severe rejection. At 30 days post-operatively the number of patients with grade III rejection decreased to 2% while 56% of patients had no sign of rejection. The 5-year survival rate was 66% while infection and arrhythmia were the most common causes of death.

CONCLUSIONS:

DCM and ICM are considered the most prevalent underlying diseases in heart transplant candidates. Ejection fraction reached normal ranges following transplant, which provides good quality of life. Low incidence of severe acute rejection demonstrates the effectiveness of our immunosuppressive therapy. In the cases of increased rejection, the patient's immunosuppressive regimen was re-assessed accordingly.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Kardiochir Torakochirurgia Pol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Irã

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Kardiochir Torakochirurgia Pol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Irã
...